Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Maternal Vaccination with a Fimbrial Tip Adhesin and Passive Protection of Neonatal Mice against Lethal Human Enterotoxigenic Escherichia coli Challenge.

Luiz WB, Rodrigues JF, Crabb JH, Savarino SJ, Ferreira LC.

Infect Immun. 2015 Dec;83(12):4555-64. doi: 10.1128/IAI.00858-15. Epub 2015 Sep 14.

PMID:
26371126
2.

A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles.

Leitner DR, Lichtenegger S, Temel P, Zingl FG, Ratzberger D, Roier S, Schild-Prüfert K, Feichter S, Reidl J, Schild S.

Front Microbiol. 2015 Aug 11;6:823. doi: 10.3389/fmicb.2015.00823. eCollection 2015.

3.

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

O'Ryan M, Vidal R, del Canto F, Carlos Salazar J, Montero D.

Hum Vaccin Immunother. 2015;11(3):601-19. doi: 10.1080/21645515.2015.1011578. Review.

PMID:
25715096
4.

Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.

Chen WH, Garza J, Choquette M, Hawkins J, Hoeper A, Bernstein DI, Cohen MB.

Clin Vaccine Immunol. 2015 Jan;22(1):129-35. doi: 10.1128/CVI.00560-14. Epub 2014 Nov 19.

5.

Designing vaccines to neutralize effective toxin delivery by enterotoxigenic Escherichia coli.

Fleckenstein JM, Sheikh A.

Toxins (Basel). 2014 Jun 10;6(6):1799-812. doi: 10.3390/toxins6061799. Review.

6.

Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines.

Kim SH, Jang YS.

Exp Mol Med. 2014 Mar 14;46:e85. doi: 10.1038/emm.2013.165. Review.

7.

Methods to assess the impact of mass oral cholera vaccination campaigns under real field conditions.

Deen J, Ali M, Sack D.

PLoS One. 2014 Feb 7;9(2):e88139. doi: 10.1371/journal.pone.0088139. eCollection 2014.

8.

Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler's diarrhea: a prospective cohort study.

López-Gigosos R, Campins M, Calvo MJ, Pérez-Hoyos S, Díez-Domingo J, Salleras L, Azuara MT, Martínez X, Bayas JM, Ramón Torrell JM, Pérez-Cobaleda MA, Núñez-Torrón ME, Gorgojo L, García-Rodríguez M, Díez-Díaz R, Armadans L, Sánchez-Fernández C, Mejías T, Masuet C, Pinilla R, Antón N, Segarra P.

Hum Vaccin Immunother. 2013 Mar;9(3):692-8. Epub 2013 Jan 16.

9.

Paediatric travel medicine: vaccines and medications.

Starr M.

Br J Clin Pharmacol. 2013 Jun;75(6):1422-32. doi: 10.1111/bcp.12035. Review.

10.

Cholera.

Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB.

Lancet. 2012 Jun 30;379(9835):2466-76. doi: 10.1016/S0140-6736(12)60436-X. Review.

11.

A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.

Harro C, Sack D, Bourgeois AL, Walker R, DeNearing B, Feller A, Chakraborty S, Buchwaldt C, Darsley MJ.

Clin Vaccine Immunol. 2011 Dec;18(12):2118-27. doi: 10.1128/CVI.05342-11. Epub 2011 Oct 12.

12.

Vaccination strategies to combat an infectious globe: oral cholera vaccines.

López-Gigosos RM, Plaza E, Díez-Díaz RM, Calvo MJ.

J Glob Infect Dis. 2011 Jan;3(1):56-62. doi: 10.4103/0974-777X.77297.

13.

New Developments in Traveler's Diarrhea.

de la Cabada Bauche J, Dupont HL.

Gastroenterol Hepatol (N Y). 2011 Feb;7(2):88-95.

14.

Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine.

Tokuhara D, Yuki Y, Nochi T, Kodama T, Mejima M, Kurokawa S, Takahashi Y, Nanno M, Nakanishi U, Takaiwa F, Honda T, Kiyono H.

Proc Natl Acad Sci U S A. 2010 May 11;107(19):8794-9. doi: 10.1073/pnas.0914121107. Epub 2010 Apr 26.

15.

Concomitant enterotoxigenic Escherichia coli infection induces increased immune responses to Vibrio cholerae O1 antigens in patients with cholera in Bangladesh.

Chowdhury F, Begum YA, Alam MM, Khan AI, Ahmed T, Bhuiyan MS, Harris JB, LaRocque RC, Faruque AS, Endtz H, Ryan ET, Cravioto A, Svennerholm AM, Calderwood SB, Qadri F.

Infect Immun. 2010 May;78(5):2117-24. doi: 10.1128/IAI.01426-09. Epub 2010 Feb 22.

16.

Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines.

Glenn GM, Francis DH, Danielsen EM.

Infect Immun. 2009 Dec;77(12):5206-15. doi: 10.1128/IAI.00712-09. Epub 2009 Sep 8. Review.

17.

Focus on acute diarrhoeal disease.

Baldi F, Bianco MA, Nardone G, Pilotto A, Zamparo E.

World J Gastroenterol. 2009 Jul 21;15(27):3341-8. Review.

18.

Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea.

López-Gigosos R, Garcia-Fortea P, Calvo MJ, Reina E, Diez-Diaz R, Plaza E.

BMC Infect Dis. 2009 May 16;9:65. doi: 10.1186/1471-2334-9-65.

19.

Vaccination greatly reduces disease, disability, death and inequity worldwide.

Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff TA, Santosham M, Schmitt HJ.

Bull World Health Organ. 2008 Feb;86(2):140-6. Review.

20.

Exploiting cholera vaccines as a versatile antigen delivery platform.

Silva AJ, Eko FO, Benitez JA.

Biotechnol Lett. 2008 Apr;30(4):571-9. Epub 2007 Nov 16. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk